Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern

Executive Summary

Genentech/Roche's Hemlibra, now FDA-approved for hemophilia A patients with inhibitors, offers a once-weekly injection, impressive efficacy with a safety concern that appears to be manageable, and a price that's at least half the cost of the established prophylaxis regimen.


Related Content

Eyes On Chugai's Hemlibra Supply Price As Sales Grow
Hemophilia Seen As Good Testing Ground For Commercializing Gene Therapy
Roche's Hemlibra Wins Expanded FDA Approval, Opening The Door To Broad Hemophilia A Opportunity
Bayer To Ship Long-Acting Hemophilia Infusion Jivi In A Jiffy
Hemlibra Effect Is Muted At Shire - For Now
Hemophilia Gene Therapy Studies Could Use Non-Inferiority Design, US FDA Suggests
Seven Clinical Trial Read-Outs Due In Q4
Phase III Updates Bode Well For Filings Of Roche's Emicizumab In Hemophilia
Hemophilia: How To Please Payers And Secure Market Share
Patient Death Casts Cloud Over Roche Emicizumab Hemophilia Trial


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts